ArticleCritical care research and practice2012
ESBLs: A Clear and Present Danger?
Article in Critical care research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- A Systematic Review on the Occurrence of Antimicrobial-ResistantBioMed research international · 2023Pooled it
- Pooled it
- Article
- Article
- Marine Cyanobacteria: A Rich Source of Structurally Unique Anti-Infectives for Drug Development.Molecules (Basel, Switzerland) · 2024Review
- Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Exploring Extended-Spectrum Beta-Lactamase (ESBL)-ProducingPathogens (Basel, Switzerland) · 2024Review
- Article
- Prevalence and risk factors for extended-spectrum β-lactamase producing antimicrobial-resistantThe Pan African medical journal · 2024Article
- Risk Factors for Bloodstream Infections Due to ESBL-ProducingPharmacy (Basel, Switzerland) · 2023Article
- Building an International One Health Strain Level Database to Characterise the Epidemiology of AMR Threats: ESBL-AmpC ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Antibiotic-Loaded Gold Nanoparticles: A Nano-Arsenal against ESBL Producer-Resistant Pathogens.Pharmaceutics · 2023Review
- A Novel Single-Tube Eicosaplex/Octaplex PCR System for the Detection of Extended-Spectrum β-Lactamases, Plasmid-Mediated AmpC β-Lactamases, and Integrons in Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
- High oral carriage of multidrug resistant Gram-negative bacilli in adolescents: the SOPKARD-Junior study.Frontiers in cellular and infection microbiology · 2023Article
- No more tears from surgical site infections in interventional pain management.The Korean journal of pain · 2023Review
- Bacterial profile and extended spectrum beta lactamase screening of urinary tract infection among asymptomatic and symptomatic pregnant women attending antenatal care in ALERT Hospital, Addis Ababa, Ethiopia.SAGE open medicine · 2023Article
- Antimicrobial resistance, virulence associated genes and phylogenetic background versus plasmid replicon types: the possible associations in avian pathogenic Escherichia coli (APEC).BMC veterinary research · 2022Article
- Antibiotic-functionalized gold nanoparticles for the detection of active β-lactamases.Nanoscale advances · 2022Article
- Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution.Microorganisms · 2022Article
- Biogenic Silver Nanoparticles Strategically Combined WithFrontiers in microbiology · 2022Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme-producing organisms are associated with a higher morbidity and mortality and greater fiscal burden. Coupled with increasing prevalence rates worldwide and an ever diminishing supply in the antibiotic armamentarium, these enzymes represent a clear and present danger to public health. This article aims to give an overview of the current situation regarding ESBLs, with a focus on the epidemiology and management of such infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.